Profile of:

Feng Huang

Dr. Feng Huang completed his medical education at the First Military Medical University in Guangzhou and Military Post-graduate Medical College in Beijing and then went on to take his post-doctoral training at the University of California, Los Angeles, United States. Today, Dr. Huang serves as Director, senior attending physician and consultant rheumatologist with the Department of Rheumatology at the Chinese PLA General Hospital in Beijing. In addition, he also serves as a professor of Medicine at the Military Post-graduate Medical College in Beijing. He has served as the vice president of the Chinese Rheumatology Association and the Chinese Rheumatologists & Immunologists Association. He has been on the advisory board of the Assessment of Spondyloarthritis International Society (ASAS). Aside from being a multi-awarded researcher, Dr. Huang is also a prolific writer, having published more than 200 articles in local and international peer-reviewed medical journals. He is the associated chief editor of the Chinese Journal of Rheumatology and served on the editorial boards of several other journals. He is also the principle investigator or consultant in several national and international clinical trials. His research interests include immunogenetics pathogenesis and novel treatment of ankylosing spondylitis.

Full name: Feng Huang

Current country: China

Membership level: Full

Type of membership: Member

Number of publications: 27

Dietary Fiber Intake Influences Changes in Ankylosing Spondylitis Disease Status. (2023)

Correlation of finger-to-floor distance with the spinal mobility, spinal function indices and initial determination of its optimal cutoff value: a multicentre case-control study. (2023)

Adherence, Efficacy, and Safety of Wearable Technology–Assisted Combined Home-Based Exercise in Chinese Patients With Ankylosing Spondylitis: Randomized Pilot Controlled Clinical Trial. (2022)

Gut microbiota changes in patients with spondyloarthritis: A systematic review. (2022)

Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials. (2022)

Symptoms compatible with Rome IV functional bowel disorder in patients with ankylosing spondylitis. (2022)

Risk of infections of biological and targeted drugs in patients with spondyloarthritis: meta-analysis of randomized clinical trials. (2022)

Bibliometric analysis of publications on enthesitis in spondyloarthritis in 2012-2021 based on web of science core collection databases. (2022)

Risk of Malignancy and Tuberculosis of Biological and Targeted Drug in Patients With Spondyloarthritis: Systematic Review and Meta-analysis of Randomized Controlled Trials. (2021)

Underweight and obesity are strong predictors of clinical outcomes in patients with ankylosing spondylitis: data from the Smart-phone SpondyloArthritis Management System. (2021)

Randomised, double-blind, placebo-controlled study of Iguratimod in the treatment of active spondyloarthritis. (2021)

Comparative Analysis of Clinical and Imaging Features of Osteomalacia and Spondyloarthritis. (2021)

Characteristics Associated with the Occurrence and Development of Acute Anterior Uveitis, Inflammatory Bowel Disease, and Psoriasis in Patients with Ankylosing Spondylitis: Data from the Chinese Ankylosing Spondylitis Prospective Imaging Cohort. (2021)

Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial. (2021)

Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: A randomized clinical trial. (2020)

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5. (2020)

Tai Chi exercise can ameliorate physical and mental health of patients with knee osteoarthritis: systematic review and meta-analysis. (2020)

Effects of types and degrees of ankylosing spondylitis hip structural damages on post-total hip arthroplasty outcome measurements. (2020)

Add-on effect of conventional synthetic disease-modifying anti-rheumatic drugs in Ankylosing Spondylitis: Data from a real-world registered study in China. (2020)

miR-214 stimulated by IL-17A regulates bone loss in patients with ankylosing spondylitis. (2020)

Effectiveness of subcutaneous tumor necrosis factor inhibitors in patients with ankylosing spondylitis: a real-world prospective observational cohort study in China. (2019)

“Mobile Health” for the Management of Spondyloarthritis and Its Application in China. (2019)

Improvement of disease management and cost-effectiveness in Chinese patients with ankylosing spondylitis using a smart-phone management system: a prospective cohort study. (2019)

Detection of Erosions in Sacroiliac Joints of Patients with Axial Spondyloarthritis Using the Magnetic Resonance Imaging Volumetric Interpolated Breath-hold Examination. (2019)

When brucellosis met the Assessment of SpondyloArthritis international Society classification criteria for spondyloarthritis: a comparative study. (2019)

Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China. (2019)

Correlation between magnetic resonance imaging (MRI) findings and the new bone formation factor Dkk-1 in patients with spondyloarthritis. (2019)